Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GB-5267 in Platinum-Resistant Ovarian Cancer
NCT07489287Phase 1Recruiting
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Aug 2026
- Primary completion
- Aug 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of GB-5267 in ovarian cancer (2 arms), sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoints: Maximum Tolerated Dose at 28 days and Dose-Limiting Toxicities at 7 days. Started Aug 2026; status: recruiting.
02
Drugs
GB-5267
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT07489287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07489287.